Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by FREEDOM55on Mar 26, 2022 11:17am
255 Views
Post# 34548134

info

info

Saliva Testing for COVID-19 Quicker, Safer Than Nasal Swabs

March 21, 2022

Washington, D.C. –  Genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs. The research is published March 21 in Microbiology Spectrum, a journal of the American Society for Microbiology.  

“That is important because people can spread COVID-19 before they know that they have it,” said coauthor Donald K. Milton, M.D., DrPH, a professor of occupational and environmental health at the Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park. “Earlier detection can reduce the disease’s spread.”  

The research was motivated by the problem that early in the pandemic, an urgent need to increase testing was accompanied by a shortage of supplies, notably nasal swabs, which were then the standard method for collecting samples for testing. 

To identify people with COVID-19 the investigators began conducting weekly tests of saliva samples from healthy community volunteers in May 2020 and continued over the next 2 years. Of the asymptomatic volunteers who tested positive, Milton and his colleagues found that those patients would typically show symptoms a day or 2 later. “That made us wonder whether saliva was better for catching pre-symptomatic patients than the traditional nasal swabs,” he said. 

To answer that question, the researchers used data from a companion study of close contacts of people with confirmed cases of COVID-19. In the study, “We collected saliva and mid-turbinate [nasal] swab samples from contacts every 2 or 3 days during their quarantine period,” said Milton. “All samples were tested using real-time reverse transcription polymerase chain reaction [RT-PCR] to detect SARS-CoV-2 and measure how much viral RNA was in the samples. We then analyzed how these results changed in the days before and after symptom onset.”  

“Early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal swabs,” notably so before onset of symptoms, according to the study, which noted that previous studies had shown that pre-symptomatic transmission plays a greater role than symptomatic transmission of SARS-CoV-2. 

The findings have implications for improving public acceptance of COVID-19 testing, reducing the cost of mass COVID-19 screening and improving the safety of healthcare workers who conduct testing. In the latter case, saliva self-testing avoids the close contact between patient and healthcare worker that nasal swabbing entails and avoids causing patients to cough and sneeze, thereby spreading virus particles as a result of swabbing the sensitive nasal passages, as well as discomfort to patients.  

“Our research supports the use of saliva in large-scale screening in schools and workplaces, as a means of improving screening rates, as well as early detection,” said Milton. “We expect that if rapid saliva tests become available, they could be a major advance from the current nasal swab-based rapid tests.”  

<< Previous
Bullboard Posts
Next >>